These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 12417281)
1. The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. Störk S; von Schacky C; Angerer P Atherosclerosis; 2002 Dec; 165(2):301-7. PubMed ID: 12417281 [TBL] [Abstract][Full Text] [Related]
2. Influence of 17beta-oestradiol on blood pressure of postmenopausal women at high vascular risk. Angerer P; Störk S; von Schacky C J Hypertens; 2001 Dec; 19(12):2135-42. PubMed ID: 11725155 [TBL] [Abstract][Full Text] [Related]
3. Hormone replacement therapy and distensibility of carotid arteries in postmenopausal women: a randomized, controlled trial. Angerer P; Kothny W; Störk S; von Schacky C J Am Coll Cardiol; 2000 Nov; 36(6):1789-96. PubMed ID: 11092645 [TBL] [Abstract][Full Text] [Related]
4. Effects of low dose hormone replacement therapy on markers of inflammation in postmenopausal women. Goudev A; Georgiev DB; Koycheva N; Manasiev N; Kyurkchiev S Maturitas; 2002 Sep; 43(1):49-53. PubMed ID: 12270582 [TBL] [Abstract][Full Text] [Related]
5. Effect of transdermal hormone replacement therapy on carotid artery wall thickness and levels of vascular inflammatory markers in postmenopausal women. Sumino H; Ichikawa S; Kasama S; Kumakura H; Takayama Y; Sakamaki T; Kurabayashi M Hypertens Res; 2005 Jul; 28(7):579-84. PubMed ID: 16335886 [TBL] [Abstract][Full Text] [Related]
6. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women. Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy. Vitale C; Cornoldi A; Gebara O; Silvestri A; Wajngarten M; Cerquetani E; Fini M; Ramires JA; Rosano GM Menopause; 2005; 12(5):552-8. PubMed ID: 16145309 [TBL] [Abstract][Full Text] [Related]
8. Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women. Sumino H; Ichikawa S; Ohyama Y; Takahashi T; Saito Y; Nakamura T; Kanda T; Kurabayashi M Am J Cardiol; 2005 Jul; 96(1):148-53. PubMed ID: 15979455 [TBL] [Abstract][Full Text] [Related]
9. Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations. Skouby SO; Gram J; Andersen LF; Sidelmann J; Petersen KR; Jespersen J Am J Obstet Gynecol; 2002 May; 186(5):969-77. PubMed ID: 12015523 [TBL] [Abstract][Full Text] [Related]
10. Effect of hormonal replacement therapy on C-reactive protein and cell-adhesion molecules in postmenopausal women. Lamon-Fava S; Posfai B; Schaefer EJ Am J Cardiol; 2003 Jan; 91(2):252-4. PubMed ID: 12521647 [No Abstract] [Full Text] [Related]
11. Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women. Wakatsuki A; Ikenoue N; Shinohara K; Watanabe K; Fukaya T Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):571-6. PubMed ID: 14699021 [TBL] [Abstract][Full Text] [Related]
12. Progestational effects of combinations of gestodene on the postmenopausal endometrium during hormone replacement therapy. Byrjalsen I; Bjarnason NH; Christiansen C Am J Obstet Gynecol; 1999 Mar; 180(3 Pt 1):539-49. PubMed ID: 10076125 [TBL] [Abstract][Full Text] [Related]
13. Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women. Tilly-Kiesi M; Kahri J; Pyörälä T; Puolakka J; Luotola H; Lappi M; Lahdenperä S; Taskinen MR Atherosclerosis; 1997 Mar; 129(2):249-59. PubMed ID: 9105568 [TBL] [Abstract][Full Text] [Related]
14. Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women. Bonduki CE; Lourenço DM; Baracat E; Haidar M; Noguti MA; da Motta EL; Lima GR Acta Obstet Gynecol Scand; 1998 Mar; 77(3):330-3. PubMed ID: 9539282 [TBL] [Abstract][Full Text] [Related]
15. Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Wakatsuki A; Okatani Y; Ikenoue N; Fukaya T Circulation; 2002 Mar; 105(12):1436-9. PubMed ID: 11914251 [TBL] [Abstract][Full Text] [Related]
16. Hormone replacement therapy does not affect plasma homocysteine in postmenopausal women with coronary artery disease. Free tissue factor pathway inhibitor antigen, a circulating anticoagulant, is related to plasma homocysteine. Os I; Os A; Sandset PM; Bølling S; Seljeflot I; Djurovic S; Westheim A Cardiology; 2002; 98(1-2):6-12. PubMed ID: 12373040 [TBL] [Abstract][Full Text] [Related]
17. Inflammatory markers and progression of subclinical atherosclerosis in healthy postmenopausal women (from the Estrogen in the Prevention of Atherosclerosis Trial). Hodis HN; St John JA; Xiang M; Cushman M; Lobo RA; Mack WJ Am J Cardiol; 2008 Apr; 101(8):1131-3. PubMed ID: 18394446 [TBL] [Abstract][Full Text] [Related]
18. Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease. Herrington DM; Werbel BL; Riley WA; Pusser BE; Morgan TM J Am Coll Cardiol; 1999 Jun; 33(7):2030-7. PubMed ID: 10362210 [TBL] [Abstract][Full Text] [Related]
19. Hormone replacement therapy does not affect the 24-hour heart rate variability in postmenopausal women: results of a randomized, placebo-controlled trial with two regimens. Fernandes EO; Moraes RS; Ferlin EL; Wender MC; Ribeiro JP Pacing Clin Electrophysiol; 2005 Jan; 28 Suppl 1():S172-7. PubMed ID: 15683490 [TBL] [Abstract][Full Text] [Related]
20. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]